Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail for tough lung cancer shows promise in small trial

NCT ID NCT00334815

Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 27, 2026 · Updated 7 times

Summary

This phase 2 pilot trial tested adding the drug bevacizumab to standard chemotherapy and radiation for patients with stage III non-small cell lung cancer that cannot be removed by surgery. The study enrolled 29 newly diagnosed patients to see if the combination is safe and helps control the cancer. Bevacizumab works by blocking blood flow to tumors, while chemo and radiation kill cancer cells directly.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bevacizumab (Avastin) plus cisplatin, etoposide, docetaxel, and radiation therapy
What this could lead to
If successful, this combination could improve control of advanced lung cancer that cannot be surgically removed, potentially extending survival.
What could go wrong
This is a small, early-phase pilot trial with only 29 participants, so results may not apply broadly. Adding bevacizumab to chemotherapy and radiation can increase side effects like bleeding or blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

29 people

The number who actually took part.

Started

Jun 2006

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically or cytologically confirmed single, primary, bronchogenic, non-small cell lung cancer (NSCLC) * Newly diagnosed disease * Unresectable disease * No more than 1 parenchymal lesions on same or opposite sides of the lungs * Meets 1 of the following stage criteria: * Stage IIIA (N2) disease meeting the following criteria: * N2 mediastinal lymph nodes must be multiple and/or bulky on CT scan or x-ray so that the patient is not a candidate for induction chemotherapy or chemoradiotherapy followed by surgical resection * N2 status must be documented by ≥ 1 of the following methods: * Histologically or cytologically confirmed N2 disease by exploratory thoracotomy, thoracoscopy, mediastinoscopy, mediastinotomy, Chamberlain procedure, Wang needle biopsy (WNB), fine needle aspiration (FNA) under bronchoscopic or CT guidance, or any other method * Node positive by fludeoxyglucose-positron emission tomography (FDG-PET) scan * Nodes \> 3 cm on CT scan * Paralyzed left true vocal cord with separate left lung primary distinct from anterior-posterior window nodes on CT scan * Stage IIIB disease meeting ≥ 1 of the following criteria: * Histologically or radiographically confirmed positive N3 nodes\*, documented by ≥ 1 of the following methods: * FNA, core needle biopsy (CNB), or excisional biopsy of supraclavicular N3 nodes * Biopsy of contralateral mediastinal N3 nodes by mediastinoscopy, mediastinotomy, or thoracotomy * FNA, CNB, or WNB under CT or bronchoscopic fluoroscopic guidance of enlarged contralateral N3 mediastinal nodes * Contralateral mediastinal nodes \> 3 cm on CT scan * Node positivity by FDG-PET scan * Right-sided primary with paralyzed left true vocal cord * T4 lesions of any size that invade the mediastinum, heart, great vessels, trachea, esophagus, vertebral body, or carina, documented by ≥ 1 of the following methods: * Written documentation of type of T4 extent if patient had a prior exploratory thoracotomy or thoracoscopy * T4 involvement of the trachea or carina by direct bronchoscopic visualization * T4 involvement of the heart, esophagus, aorta, or vertebral body by CT scan, MRI, or transesophageal ultrasound * T4 involvement of the mediastinum by CT scan or MRI if, in the absence of the above organ involvement, there is soft tissue extension directly into the mediastinal space\*\* * Meets 1 of the following risk criteria: * Low risk disease, meeting the following criteria: * Non-squamous cell NSCLC, including adenocarcinoma, bronchoalveolar cell carcinoma, or large cell carcinoma * If mixed histology, the squamous cell carcinoma component must be \< 50% * Histology or cytology from involved mediastinal or supraclavicular lymph nodes allowed if a separate distal primary lesion is clearly evident on radiographs (i.e., second biopsy not required) * No primary tumor with cavitation and/or tumor within 1 cm of a major vessel * No hemoptysis (i.e., bright red blood ≥ ½ teaspoon) in the past 28 days * High-risk\* disease, meeting ≥ 1 of the following criteria: * Squamous cell NSCLC * If mixed histology, the squamous cell component must be ≥ 50% * Tumor with any histology that has cavitation or is located within 1 cm of a major vessel * No aortic involvement * Any histology and hemoptysis (i.e., bright red blood ≥ ½ teaspoon) within past 28 days * Measurable or nonmeasurable disease by CT scan or MRI * Pleural effusions, ascites, and laboratory parameters are not acceptable as the only evidence of disease * No pleural effusion except for small pleural effusion visible on CT scan or MRI alone * No pericardial effusions * No metastatic disease involving the contralateral chest, liver, or adrenals confirmed by CT scan of the upper abdomen or by chest CT scan with complete liver and adrenals in the report * Patients must be offered participation in SWOG-S9925 (Lung Cancer Specimen Repository Protocol) * No brain metastases by CT scan or MRI * No evidence of cavitation * Creatinine normal * Creatinine clearance ≥ 50 mL/min * FEV\_1 ≥ 2.0 liters OR predicted FEV\_1 of the contralateral lung \> 800 mL * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Urine protein: creatinine ratio ≤ 0.5 by urinalysis OR urine protein \< 1,000 mg by 24-hour urine collection * INR \< 1.5 * Zubrod performance status 0-1 * No sensory neuropathy \> grade 1 * No cerebrovascular accident within the past 6 months * No myocardial infarction or unstable angina within the past 6 months * No uncontrolled hypertension * No New York Heart Association class II-IV congestive heart failure * No serious cardiac arrhythmia requiring medication * No clinically significant peripheral vascular disease * No evidence of bleeding diathesis or coagulopathy * No pathologic condition other than lung cancer that carries a high risk of bleeding * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * No serious, nonhealing wound, ulcer, or bone fracture * No other prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer for which the patient is currently in complete remission, or other cancer for which the patient has been disease-free for 5 years * Not pregnant or nursing * No nursing during and for ≥ 6 months after the last dose of bevacizumab * Negative pregnancy test * Fertile patients must use effective contraception during and for ≥ 6 months after the last dose of bevacizumab * Must have pre-treatment simulation demonstrating a V20 ≤ 35% with planned radiation dose of 6,480 cGy * No prior surgical resection * Prior exploratory thoracotomy, mediastinoscopy, excisional biopsy, or similar surgery allowed for diagnosing, staging, or determining potential resectability of lung tumor * No prior chemotherapy or radiotherapy for lung cancer * No prior radiotherapy to the neck or thorax * At least 4 weeks since prior thoracic or other major surgery (excluding mediastinoscopy) and recovered * More than 7 days since prior FNA, CNB, or mediastinoscopy * No other concurrent anticancer therapy, including chemotherapy, radiotherapy, or biologic agents * No other concurrent investigational drugs * No concurrent major surgical procedures * No concurrent full-dose anticoagulants (e.g., low-molecular weight and unfractionated heparin or warfarin) * Low-dose warfarin (i.e., 1 mg) is allowed to prevent clotting of an infusaport or central line * No concurrent brachytherapy, radiopharmaceuticals, high linear energy transfer radiation (i.e., fast neutrons), particle therapy (i.e., protons, carbon, or helium), and/or altered fractionation schemes * No concurrent intensity-modulated radiotherapy * No concurrent prophylactic contralateral hilar or supraclavicular lymph node radiotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung adenosquamous lung carcinoma lung adenocarcinoma lung large cell carcinoma minimally invasive lung adenocarcinoma non-small cell lung carcinoma squamous cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung adenocarcinoma Lung adenosquamous carcinoma Lung large cell carcinoma Lung squamous cell carcinoma Minimally invasive lung adenocarcinoma Stage IIIA lung non-small cell cancer ajcc V7 Stage IIIB lung non-small cell cancer ajcc V7

Contacts and locations

Locations

  • Arnot Ogden Medical Center/Falck Cancer Center

    Elmira, New York, 14905, United States

  • Audie L Murphy VA Hospital

    San Antonio, Texas, 78229, United States

  • Ballad Health Cancer Care - Norton

    Norton, Virginia, 24273, United States

  • Benefis Sletten Cancer Institute

    Great Falls, Montana, 59405, United States

  • Cancer Centers of Central Florida PA

    Leesburg, Florida, 34788, United States

  • Dana-Farber Cancer Institute at Boston Medical Center - Brighton

    Brighton, Massachusetts, 02135, United States

  • Danville Regional Medical Center

    Danville, Virginia, 24541, United States

  • Denver Health Medical Center

    Denver, Colorado, 80204, United States

  • Edward Hospital/Cancer Center

    Naperville, Illinois, 60540, United States

  • Fremont - Rideout Cancer Center

    Marysville, California, 95901, United States

  • Gene Upshaw Memorial Tahoe Forest Cancer Center

    Truckee, California, 96161, United States

  • HaysMed

    Hays, Kansas, 67601, United States

  • Highland Clinic

    Shreveport, Louisiana, 71105, United States

  • Highland Hospital

    Rochester, New York, 14620, United States

  • Highlands Oncology Group - Rogers

    Rogers, Arkansas, 72758, United States

  • Hutchinson Regional Medical Center

    Hutchinson, Kansas, 67502, United States

  • Kansas City Veterans Affairs Medical Center

    Kansas City, Missouri, 64128, United States

  • LSU Health Sciences Center at Shreveport

    Shreveport, Louisiana, 71103, United States

  • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

    Savannah, Georgia, 31405, United States

  • Loyola University Medical Center

    Maywood, Illinois, 60153, United States

  • McLaren Cancer Institute-Macomb

    Mount Clemens, Michigan, 48043, United States

  • Montana Cancer Consortium NCORP

    Billings, Montana, 59102, United States

  • Montrose Memorial Hospital

    Montrose, Colorado, 81401, United States

  • MultiCare Allenmore Hospital

    Tacoma, Washington, 98405, United States

  • MultiCare Auburn Medical Center

    Auburn, Washington, 98001, United States

  • MultiCare Good Samaritan Hospital

    Puyallup, Washington, 98372, United States

  • Northbay Cancer Center

    Vacaville, California, 95687, United States

  • Novant Health Presbyterian Medical Center

    Charlotte, North Carolina, 28204, United States

  • Olathe Cancer Center

    Olathe, Kansas, 66061, United States

  • Oregon Health and Science University

    Portland, Oregon, 97239, United States

  • Portland VA Medical Center

    Portland, Oregon, 97239, United States

  • Providence - Saint Peter Hospital

    Olympia, Washington, 98506-5166, United States

  • Providence Hospital

    Mobile, Alabama, 36608, United States

  • Providence Regional Cancer System-Centralia

    Centralia, Washington, 98531, United States

  • Providence Santa Rosa Memorial Hospital

    Santa Rosa, California, 95405, United States

  • Rocky Mountain Regional VA Medical Center

    Aurora, Colorado, 80045, United States

  • Roper Hospital

    Charleston, South Carolina, 29401, United States

  • Saint Bernards Regional Medical Center

    Jonesboro, Arkansas, 72401, United States

  • Saint Clare Hospital

    Lakewood, Washington, 98499, United States

  • Saint Francis Hospital

    Federal Way, Washington, 98003, United States

  • Saint Joseph Medical Center

    Tacoma, Washington, 98405, United States

  • Salina Regional Health Center

    Salina, Kansas, 67401, United States

  • Shaw Cancer Center

    Edwards, Colorado, 81632, United States

  • Southeast Clinical Oncology Research Consortium NCORP

    Winston-Salem, North Carolina, 27104, United States

  • The Don and Sybil Harrington Cancer Center

    Amarillo, Texas, 79106, United States

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California, 92868, United States

  • UCHealth University of Colorado Hospital

    Aurora, Colorado, 80045, United States

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • UT MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • University Hospital

    San Antonio, Texas, 78229, United States

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas, 72205, United States

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, 95817, United States

  • University of Kansas Cancer Center

    Kansas City, Kansas, 66160, United States

  • University of Kansas Health System Saint Francis Campus

    Topeka, Kansas, 66606, United States

  • University of Mississippi Medical Center

    Jackson, Mississippi, 39216, United States

  • University of Rochester

    Rochester, New York, 14642, United States

  • University of Tennessee Health Science Center

    Memphis, Tennessee, 38163, United States

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas, 78229, United States

  • Valley View Hospital Cancer Center

    Glenwood Springs, Colorado, 81601, United States

  • Wayne State University/Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Wellmont Holston Valley Hospital and Medical Center

    Kingsport, Tennessee, 37660, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.